Stimulating Percutaneous Array for Urinary Reflex Control (SPARC)

NCT07149103 | Not Yet Recruiting

• 1 other identifier: CP-001
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

The Confidanz Smart Patch System consists of a Smart Patch containing one transcutaneous gel electrode and one percutaneous microneedle array electrode that sits directly superficial to the posterior tibial nerve. An applicator is used by the patient to deploy the microneedles into the skin. A Capital Stimulation Unit (CSU) is magnetically aligned with the Smart Patch and generates biphasic current wave form to the posterior tibial nerve through the patch. The CSU is connected to a mobile application via Bluetooth, allowing control over the stimulation intensity parameters. Primary Objective: To investigate the safety of the Confidanz Smart Patch System for adults diagnosed with idiopathic overactive bladder. Secondary Objective: To measure the reduction from baseline in average incontinence events (IE) per day at 6- and 12-weeks. Primary Hypothesis: The use of the Confidanz Smart Patch System is safe for use in adults with idiopathic overactive bladder.

Conditions

Over Active Bladder

Keywords

Over active bladder; Incontinence; Ideopathic Over active bladder; Percutaneous Tibial Nerve Stimulation (PTNS)

Outcome Measures

Primary Outcomes (1)

• Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Number of AEs and SAEs occurring throughout the study

  Up to 12 weeks

Secondary Outcomes (1)

• Change from baseline in average voids per day at 6- and 12-weeks.

  Up to 12 weeks

Study Arms (2)

Treatment Arm

EXPERIMENTAL

The treatment arm will undergo the experimental treatment

Other: Percutaneous Tibial Nerve Stimulation

SHAM ARM

PLACEBO COMPARATOR

The sham arm will undergo the same procedure as the treatment group but the therapy will not be switched on

Other: Placebo

Interventions

Percutaneous Tibial Nerve Stimulation OTHER

By wearing the Confidanz Smart Patch, the Tibial Nerve will be stimulated

Treatment Arm

Placebo OTHER

No active stimulation will be provided

SHAM ARM

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing and able to give informed consent for participation in the investigation
• Is aged 18 years or older
• Has been diagnosed with idiopathic overactive bladder (OAB) by a qualified urologist (FRACS) or gynaecologist (FRANZCOG)
• Eligibility is based on meeting the criteria for an OAB, defined by the International Continence Society as an average urinary frequency: ≥8 voids and ≥1 urgency episode (with or without incontinence) per 24 hours
• Clinically acceptable laboratory results within 30 days of enrolment Urinalysis: Dipstick (Leukocytes \& Nitrites)
• In the Investigator's opinion, participant is able and willing to comply with all trial requirements
• Willing to allow their general practitioner and/or other specialists to be aware of their participation in the trial.

You may not qualify if:

• Presence of urinary tract infection based on a positive dipstick AND positive mid-stream urine (MSU) test within 4 weeks prior to therapy commencement.
• Female participant who is pregnant, lactating or planning pregnancy during the trial.
• History of bladder augmentation/cystoplasty
• Morbid obesity (BMI greater than 35)
• Poorly controlled diabetes mellitus (HbA1c \> 7.5% (based on diabetic study)
• Intravesical injection of botulinum toxin within 12 months of study enrolment.
• Patients who have failed intravesical Botox therapy.
• Patients with neurogenic lower urinary tract dysfunction or relevant neurological disease
• A treatment within the previous year of neuromodulation (TNS or sacral neuromodulation) for OAB.
• Participant with pacemakers or implantable defibrillators, or other active implantable devices (e.g., spinal cord stimulators, bladder neurostimulators)
• Participant who have participated in another research trial involving an investigational product in the past 12 weeks.
• Participant on medication therapy for OAB who have not gone through a two-week washout period during which time medications were discontinued.
• Participant is in the investigators opinion, unable to comply with trial requirements.
• Participant has inflamed, infected or otherwise compromised skin in the treatment area.
• Participant with a bleeding disorder e.g., haemophilia

Sponsors & Collaborators

• Australis Scientific PTY LTD: lead

Study Sites (2)

Vincent Tse Pty Ltd

Chatswood, New South Wales, 2067, Australia

Location

AndroUrology Centre

Spring Hill, Queensland, 4001, Australia

Location

Central Study Contacts

Nigel D'Silva

CONTACT

+61466411877; nigel.dsilva@australisscientific.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 21, 2025
• First Posted: August 29, 2025
• Study Start: August 29, 2025
• Primary Completion: January 30, 2026
• Study Completion: January 30, 2026
• Last Updated: August 29, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

AU (2)